Please login to the form below

Not currently logged in
Email:
Password:

PD-1/PD-L1 inhibitor

This page shows the latest PD-1/PD-L1 inhibitor news and features for those working in and with pharma, biotech and healthcare.

Tecentriq misses the mark in advanced ovarian cancer

Tecentriq misses the mark in advanced ovarian cancer

PD-L1 inhibitor failed to improved progression-free survival. Roche’s Genentech division has reported that Tecentriq, plus Avastin, was unable to improve progression-free survival as a front-line treatment ... The FDA approval for Imfinzi makes AZ’s

Latest news

More from news
Approximately 1 fully matching, plus 58 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Aurora Healthcare Communications

We're a leading healthcare strategic communications agency helping pharmaceutical companies adapt fast to improve the lives of patients and healthcare...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics